27 results
PRE 14A
SYRS
Syros Pharmaceuticals Inc.
12 Apr 24
Preliminary proxy
4:30pm
Islander
White
Two or More Races or Ethnicities
Member of the LGBTQ+ Community
Did Not Disclose
Board of Director Meetings and Attendance
Our board … of our common stock beneficially owned by them, subject to community property laws, where applicable. Except as otherwise set forth below, the address
8-K
EX-99.1
SYRS
Syros Pharmaceuticals Inc.
8 Jan 24
Regulation FD Disclosure
7:06am
diagnosed unfit AML Educating and preparing the treatment community for tamibarotene and RARA overexpression Planning distribution and sales … and preparing the treatment community for tamibarotene and RARA overexpression Planning distribution and sales infrastructure Partnered with Qiagen to ensure RARA testing availability at launch Pre-launch activities ��
424B3
gjg5 7rh3gw8
8 Aug 22
Prospectus supplement
5:47pm
S-4
y9iq7ka
18 Jul 22
Registration of securities issued in business combination transactions
7:58am
425
8cm yfwfekvvctskx9a
5 Jul 22
Business combination disclosure
7:14am
8-K
EX-2.1
r01b1rh mn48wm
5 Jul 22
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
7:07am
8-K
EX-10.1
a74gy0c3g ug0bo
11 Jan 19
Entry into a Material Definitive Agreement
5:02pm